Literature DB >> 18840922

Confounding by severity and indication in observational studies of antidepressant effectiveness.

Scott B Patten1.   

Abstract

BACKGROUND: It has been suggested that antidepressants worsen the course of major depressive disorder. Epidemiological data have sometimes been cited in support of this idea, but such estimates are vulnerable to confounding. The objective of this study was to assess episode incidence and recovery in relation to antidepressant use, adjusting for symptom severity.
METHODS: Random digit dialing was used to select a sample of n=3304 community residents. Each respondent was then assessed with a baseline interview followed by a series of six subsequent interviews spaced two weeks apart. The brief Patient Health Questionnaire (PHQ-9) was used to detect depressive episodes during follow-up and to provide ratings of symptom severity. Grouped time proportional hazards models were used to assess confounding by producing estimates of the association between antidepressant use and major depression incidence and prognosis adjusted for baseline symptom severity.
RESULTS: Antidepressant use in initially non-depressed respondents was associated with a markedly higher incidence of depression (Hazard Ratio, HR = 3.9, 95% CI 1.8 â 8.5). With adjustment for the depression severity score in the two weeks preceding the emergence of a new episode, this effect diminished markedly and was no longer statistically significant (HR = 1.2, 95% CI 0.6 â 2.7, p = 0.57). Antidepressant use was also associated with a lower rate of recovery from major depression (HR = 0.8, 95% CI 0.5 â 1.2, p = 0.27), but this effect also moved towards the null value after adjustment for baseline severity (HR = 0.9, 95% CI 0.6 â 1.5).
CONCLUSIONS: Antidepressant medication use is confounded with symptom severity. Observational studies seeming to show harmful effects of antidepressants are subject to bias as a result. Key words: Antidepressive agent; longitudinal studies; epidemiology; methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840922

Source DB:  PubMed          Journal:  Can J Clin Pharmacol        ISSN: 1198-581X


  6 in total

1.  Major depressive disorder and stroke risks: a 9-year follow-up population-based, matched cohort study.

Authors:  Cheng-Ta Li; Ya-Mei Bai; Pei-Chi Tu; Ying-Chiao Lee; Yu-Lin Huang; Tzeng-Ji Chen; Wen-Han Chang; Tung-Ping Su
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

2.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Shvetank Bhatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

3.  Associations between depressive symptoms and incident ESRD in a diabetic cohort.

Authors:  Margaret K Yu; Noel S Weiss; Xiaobo Ding; Wayne J Katon; Xiao-Hua Zhou; Bessie A Young
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 8.237

4.  Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9).

Authors:  P K Crane; L E Gibbons; J H Willig; M J Mugavero; S T Lawrence; J E Schumacher; M S Saag; M M Kitahata; H M Crane
Journal:  AIDS Care       Date:  2010-07

5.  Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations.

Authors:  Anna-Sophie Rommel; Natalie C Momen; Nina Maren Molenaar; Esben Agerbo; Veerle Bergink; Trine Munk-Olsen; Xiaoqin Liu
Journal:  Acta Psychiatr Scand       Date:  2022-02-18       Impact factor: 7.734

Review 6.  Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications.

Authors:  Rita Khoury; George T Grossberg
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.